Dr. Cohen is the Chief Executive Officer of Wren Therapeutics. Dr. Cohen has a background as a research scientist, as well as experience in venture capital and strategy consulting. He was previously a Research Fellow in Biophysical Chemistry at the Centre for Misfolding Diseases at the University of Cambridge, where he worked with Wren’s other scientific founders on the chemical kinetics of protein misfolding and aggregation. Dr. Cohen's research included the development of the network kinetics theoretical framework and its application to multiple disease systems. In particular, he was part of the team that established the central role of secondary nucleation in the misfolding and aggregation pathway.
Dr. Cohen was formerly an investment director at Malin plc, and a consultant in the London office of Boston Consulting Group (BCG) where he advised leading healthcare and technology companies across Europe and the US. He is also currently the Entrepreneur-in-Residence at St John’s College, University of Cambridge.
Dr. Cohen graduated with bachelors and masters in Natural Sciences (Physics) and a PhD in Biophysical Chemistry from the University of Cambridge. He also spent a year as a Visiting Fellow at Harvard University.
Dr. Cohen is co-author of more than 30 scientific papers. His TED talk on Alzheimer’s disease has been viewed more than 2 million times.
Publications by Samuel Cohen PhD
Drug discovery | Sep 2020
Kinetic fingerprints differentiate the mechanisms of anti-Aβ antibodies
Linse S, Scheidt T, Bernfur K, Vendruscolo M, Dobson CM, Cohen SI, Sileikis E, Lundquist M, Qian F, O’Malley T, Bussiere T, Weinreb PH, Xu CK, Meisl G, Devenish SR, Knowles TP, Hansson O
Disease Mechanisms | Apr 2020
Determining dynamics during amyloid assembly
Michaels TC, Šarić A, Curk S, Bernfur K, Arosio P, Meisl G, Dear AJ, Cohen SI, Dobson CM, Vendruscolo M, Linse S and Knowles TP.
Drug discovery | Oct 2018
SAR by kinetics for drug discovery in protein misfolding diseases
Chia S, Habchi J, Michaels TC, Cohen SI, Linse S, Dobson CM, Knowles TP and Vendruscolo M.
Drug discovery | Feb 2017
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Perni M, Galvagnion C, Maltsev A, Meisl G, Müller MB, Challa PK, Kirkegaard JB, Flagmeier P, Cohen SI, Cascella R, Chen SW, Limbocker R, Sormanni P, Heller GT, Aprile FA, Cremades N, Cecchi C, Chiti F, Nollen EA, Knowles TP, Vendruscolo M, Bax A, Zasloff M and Dobson CM.